Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients

Date: 
3 Nov 2017
Source: 
Science
Audience: 
Patients and public
Type of resource: 
Research

Pre-clinical mouse models suggest that the gut microbiome modulates tumor response to checkpoint blockade immunotherapy; however, this has not been well-characterized in human cancer patients. Here we examined the oral and gut microbiome of melanoma patients undergoing anti-PD-1 immunotherapy (n=112).

 

Click hear to read the Research article in full